Collegium Pharmaceutical(COLL) ZACKS·2024-11-13 15:45Core Insights - The Zacks Rank system focuses on earnings estimates and revisions to identify winning stocks, while also considering trends in value, growth, and momentum [1] - Value investing aims to find undervalued companies through fundamental analysis and traditional valuation metrics [2] Company Analysis: Collegium Pharmaceutical (COLL) - COLL holds a Zacks Rank of 2 (Buy) and a Value grade of A, indicating strong interest from investors [3] - The P/S ratio for COLL is 1.69, significantly lower than the industry average of 3.29, suggesting it is undervalued [4] - COLL's P/CF ratio is 5.51, compared to the industry's average of 10.45, indicating a solid cash outlook [5] - Over the past 12 months, COLL's P/CF has fluctuated between 5.26 and 8.61, with a median of 6.44 [5] Company Analysis: Jazz Pharmaceuticals (JAZZ) - JAZZ also has a Zacks Rank of 2 (Buy) and a Value Score of A, making it another attractive option for investors [6] - The forward P/E for JAZZ is 5.87, significantly lower than the industry average of 58.22, and its PEG ratio is 0.84 compared to the industry average of 2.36 [6] - JAZZ's Forward P/E has ranged from 4.97 to 6.87, with a median of 5.62, while its PEG ratio has varied between 0.64 and 1.44, with a median of 1.07 [7] - The P/B ratio for JAZZ is 1.88, slightly above the industry's average of 1.35, with a 52-week range of 1.59 to 2.27 and a median of 1.89 [7] Conclusion - Both COLL and JAZZ exhibit strong value metrics, suggesting they are likely undervalued and present impressive investment opportunities based on their earnings outlook [8]